Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Fusiones oncogénicas susceptibles de ser moduladas por fármacos

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20160613002
Publicado:
08/06/2017
Caducidad:
18/12/2017
Resumen:
Científicos de una universidad alemana han identificado fusiones del gen de Neuregulina 1 como marcadores ideales de diagnóstico y pronóstico y dianas para varios tumores. La detección de estas fusiones puede ayudar a decidir el tratamiento médico adecuado (por ejemplo, para adenocarcinoma pulmonar mucinoso invasivo) y constituyen un blanco prometedor para el desarrollo de intervenciones médicas. La universidad busca institutos de la industria farmacéutica con el fin de establecer acuerdos de licencia o cooperación técnica.

Details

Tittle:
Druggable oncogenic fusions
Summary:
Scientists of a German university identified Neuregulin 1 gene fusions as ideal diagnostic and prognostic markers and targets for various tumours. The detection of these fusions may aid making a decision on the appropriate medical treatment and are a promising target for the development of medical interventions. The German university offers a license agreement and is open for further technical cooperation with institutes active in the pharmaceutical industry.
Description:
Cancer patients frequently bear therapeutically relevant genome alteration. For instance, lung adenocarcinomas of patients that have never smoked carry genome alterations affecting kinases, such as EGFR (epidermal growth factor receptor) mutations and translocations affecting various kinases (specifically ALK, ROS1, and RET genes). These patients can be effectively treated with an ever-growing number of kinase inhibitors. However, despite substantive cancer genome sequencing efforts a majority of tumours still lacks therapeutically tractable alterations.
Scientists of a German university identified Neuregulin 1 (NRG1) gene fusions as ideal diagnostic and prognostic markers and targets for various tumours.
This is a detailed description of the new gene fusions:
The MTSS1-NRG1 fusion event has e.g. been detected in patients with small cell lung cancer and the gene fusion CD74-NRG1 has been shown to occur frequently in never smokers with invasive mucinous lung adenocarcinoma lacking KRAS mutation. The latter has been verified by several other groups.CD74-NRG1 was found to signal through induction of ERBB2-ERBB3 heterodimers. In light of the multitude of available drugs or drugs in clinical trials targeting ERBB2, ERBB3 and their downstream pathways, the detection of CD74-NRG1 fusions may aid making a decision on the appropriate medical treatment e.g. for invasive mucinous lung adenocarcinomas. Furthermore, the fusion itself represents a promising target for the development of medical interventions. Thus, these findings position MTSS1-NRG1 and CD74-NRG1 as druggable oncogenic fusions.
The German university offers a license agreement and is open for a further technical cooperation.
Advantages and Innovations:
- CD74-NRG1 is a novel fusion gene which - by itself or its products - can be used both for diagnosis and as a target for medical intervention e.g. in invasive mucinous adenocarcinomas.
- MTSS1-NRG1 represents a further druggable oncogenic NRG1 fusion gene.
- The signalling pathways within the cell are known and thus give information on possible adverse effects of therapeutic agents and underpin the scientific accuracy of medication.
- The fusion gene enables stratification of patients for ERBB2 and/or ERBB3 inhibitor treatment.
Stage of Development:
Prototype available for demonstration
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
A patent application has been filed in the European Patent Office and in the American Patent Office.

Partner sought

Type and Role of Partner Sought:
The German university offers a license agreement and is open for further technical cooperation with companies and institutes active in the pharmaceutical industry.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06003002 Expresión genética, investigación proteómica
06002005 Ingeniería genética
06001015 Productos farmacéuticos / medicamentos
06001013 Tecnología médica / ingeniería biomédica